This is a non-core endpoint: only basic statistics are computed.
See these related core endpoints for full statistics:
L02BX Other hormone antagonists and related agents
RX_L02BX
No definition available.
Endpoint definition
↥Report an error or suggest an improvement for this endpoint codes
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
519972 |
1. Apply sex-specific ruleNone |
519972 |
2. Check conditionsNone |
519972 |
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters:
1 out of 7 registries used, show all original rules. |
1925 |
4. Check minimum number of events
Min. number of events
3
|
1925 |
5. Include endpointsNone |
1925 |
6. Filter based on genotype QC (FinnGen only) |
1861 |
Control definitions (FinnGen only)
Controls for this endpoint are individuals that are not cases.
Extra metadata
- First used in FinnGen datafreeze
- DF3
Similar endpoints
↥List of similar endpoints to
L02BX Other hormone antagonists and related agents
based on the number of shared cases.
Similar with more cases:
- Malignant neoplasm of prostate, including Hilmo
- Malignant neoplasm, wide definition for exclusion
- Any operation in hilmo
- Any event in hilmo or specialist outpatient
- Any prescribed medicine buy
Similar with less cases:
None
Case counts by codes
↥
Summary Statistics
↥-FinRegistry-
This endpoint is excluded from FinRegistry analyses (omitted endpoint).
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 1861 | - | 1861 |
| Unadjusted period prevalence (%) | 0.85 | - | 0.85 |
| Median age at first event (years) | 73.64 | - | 73.64 |
-FinnGen-
Age distribution of first events
-FinnGen-
Year distribution of first events
-FinnGen-
Cumulative Incidence Function
Not a core endpoint, no data to show.
CodeWAS
↥CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.
This is a new tool, please reach out using the contact form for feedback and improvement ideas.
First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.
Matched cohort
- Matched cases
- 1925
- Matched controls
- 19250
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
KE3AT
NOMESCO Finland
Transrectal gold marker implantation in prostate under ultrasound guidance
10.2
313.5
394
475
YL1BD
NOMESCO Finland
Extensive CT examination of pelvis for dose design of radiotherapy
12.7
307.7
357
338
1523, ,
Kela drug reimbursment
86.4
307.7
365
52
XX3DW
NOMESCO Finland
Time consuming IT work
7.2
307.7
741
1530
3054, ,
Kela drug reimbursment
86.1
307.7
364
52
KE1AT
NOMESCO Finland
Biopsy of prostata with ultrasoudnguidance
11.2
307.7
978
1628
L02BX03
ATC
abiraterone; oral
737.9
307.7
859
21
WD205
NOMESCO Finland
Therapy of methastized malignancy with hormones
90.2
307.7
342
46
NK6AN
NOMESCO Finland
Total body bone isotope imaging
20.7
307.7
527
344
163
Kela drug reimbursment
Abiraterone and enzalutamide
313.6
307.7
999
66
WF049
NOMESCO Finland
Radiotherapy of metastasis
20.0
307.7
614
441
C61
ICD-10 Finland
Malignant neoplasm of prostate
1420.3
307.7
1917
2870
WF002
NOMESCO Finland
Radical radiotherapy
7.8
307.7
630
1129
C79.5
ICD-10 Finland
Secondary malignant neoplasm of bone and bone marrow
51.7
307.7
708
214
L02AE02
ATC
leuprorelin; implant, parenteral
20.0
307.7
1043
1074
WD105
NOMESCO Finland
Cystostatic therapy of methastized malignancy
21.7
307.7
660
451
L02BB03
ATC
bicalutamide; oral
19.6
307.7
740
594
8140/3-C61.9
ICD-O-3
Adenocarcinoma, NOS, of prostate gland
124.2
307.7
1833
2661
352
Kela drug reimbursment
Abiraterone and enzalutamide
264.9
307.7
727
44
ZX112
NOMESCO Finland
Subcutaneous
17.9
307.7
289
188
WD225
NOMESCO Finland
Demanding therapy of methastized malignancy with hormones
67.6
307.7
354
64
M05BX04
ATC
denosumab; parenteral
42.6
307.7
857
356
L02BX02
ATC
degarelix; parenteral
1873.7
307.7
1422
29
Z51.5
ICD-10 Finland
Palliative care
7.8
307.7
710
1334
Y77
ICPC
Malignant neoplasm prostate
49.5
307.7
1222
653
C79.8
ICD-10 Finland
Secondary malignant neoplasm of other specified sites
15.0
307.7
500
440
H02AB02
ATC
dexamethasone; systemic
12.3
307.7
879
1230
L03AA13
ATC
pegfilgrastim; parenteral
17.8
307.7
374
257
L02BB04
ATC
enzalutamide; oral
166.6
307.7
801
82
A12AX
ATC
Calcium, combinations with vitamin D and/or other drugs
13.5
307.7
1439
3467
116
Kela drug reimbursment
Prostate cancer
972.9
307.7
1902
1508
A03FA01
ATC
metoclopramide; systemic, rectal
6.7
307.7
913
2271
JN4BD
NOMESCO Finland
Extensive body CT
6.1
297.5
688
1601
N02AA05
ATC
oxycodone; systemic
5.4
292.5
945
2932
WD305
NOMESCO Finland
Simple therapy of methastized malignancy with biomodifiers
22.6
282.5
212
105
L02AE04
ATC
triptorelin; parenteral
15.2
275.4
254
191
WZC00
NOMESCO Finland
Treatment plan or consultation
5.1
271.1
1219
4854
JN4AD
NOMESCO Finland
Body CT examination
5.6
264.2
662
1637
L03AA14
ATC
lipegfilgrastim; parenteral
30.3
260.5
174
63
ZX012
NOMESCO Finland
Radiotherapy with large shaped fields - isocentric therapy
7.9
247.7
385
593
WF004
NOMESCO Finland
Palliative radiotherapy
11.6
247.7
271
267
R74.8
ICD-10 Finland
Abnormal levels of other serum enzymes
5.6
242.6
589
1406
C77.8
ICD-10 Finland
Secondary and unspecified malignant neoplasm: Lymph nodes of multiple regions
36.4
195.9
123
36
XKD00
NOMESCO Finland
Uroflowmetry
4.0
195.3
1092
4766
XX9AN
NOMESCO Finland
Complementary isotope examination or additional picture
69.4
192.5
105
16
WD215
NOMESCO Finland
Multiple therapy of methastized malignancy with hormones
73.2
192.3
104
15
YL1AD
NOMESCO Finland
CT examination of pelvis for dose design of radiotherapy
9.2
192.3
249
306
A04AA02
ATC
granisetron; systemic, transdermal
6.3
189.8
361
678
KC1EE
NOMESCO Finland
Ultrasound measurement of residual urine
3.8
180.6
939
3855
1CD02, ,
NOMESCO Finland
68.8
179.4
98
15
L02AE03
ATC
goserelin; implant
15.3
174.1
156
110
WVA30, ,
SPAT
6.5
173.9
317
569
A79
ICPC
Malignancy NOS
13.1
169.1
167
139
A04AA01
ATC
ondansetron; systemic, rectal
5.5
157.3
346
738
R86.0
ICD-10 Finland
Abnormal findings in specimens from male genital organs, abnormal level of enzymes
6.4
148.9
269
476
ZX090
NOMESCO Finland
Other technic of radiotherapy
8.5
147.2
200
259
D40.0
ICD-10 Finland
Neoplasm of uncertain or unknown behaviour: Prostate
7.4
143.7
221
330
M87.1
ICD-10 Finland
Osteonecrosis due to drugs
38.4
142.5
88
24
C77.5
ICD-10 Finland
Secondary and unspecified malignant neoplasm: Intrapelvic lymph nodes
34.5
139.9
89
27
ZX070
NOMESCO Finland
Intensity modified radiotherapy
8.4
137.9
188
244
2BX02, ,
NOMESCO Finland
57.3
136.5
77
14
YJ2VG
NOMESCO Finland
MRI examination of pelvis with high intensity magnet for dose design of radiotherapy
8.2
136.4
191
256
G03HA01
ATC
cyproterone; systemic
14.6
132.3
121
88
SPAT1256
SPAT
Intramuscular and subcutaneous injection
3.2
131.3
1203
6597
XX7FT
NOMESCO Finland
Radioyttrium therapy with connected antibody
274.1
126.7
128
5
NK6BQ
NOMESCO Finland
Whole body extensive bone SPET with low dose CT
16.4
120.5
103
66
YN7AD
NOMESCO Finland
CT examination of spine for dose design of radiotherapy
28.1
119.4
81
30
A06AH03
ATC
naloxegol; oral
10.3
117.5
135
140
YN7BD
NOMESCO Finland
Extensive CT examination of spine for dose design of radiotherapy
31.6
111.8
73
24
N13.3
ICD-10 Finland
Other and unspecified hydronephrosis
7.4
111.5
169
247
WZC30
NOMESCO Finland
Teaching
3.2
111.2
577
2247
NK6AQ
NOMESCO Finland
Whole body bone SPET with low dose CT
28.5
109.6
74
27
KE1DR
NOMESCO Finland
Prostate metabolic PET with CT
21.1
106.9
81
40
JN5ER
NOMESCO Finland
PET-CT of receptors in whole body
14.8
102.9
93
66
JN4LR
NOMESCO Finland
Extensive PET-CT of receptors in whole body
45.0
102.7
61
14
XX1XQ
NOMESCO Finland
Other SPECT-CT
138.7
99.1
105
8
U77
ICPC
Malignant neopl urinary tract other
29.2
97.1
65
23
C77.2
ICD-10 Finland
Secondary and unspecified malignant neoplasm: Intra-abdominal lymph nodes
18.4
97.0
78
44
N02AB03
ATC
fentanyl; nasal, sublingual, transdermal
4.7
96.6
244
576
TKE00
NOMESCO Finland
Needle biopsy of prostate
3.7
91.5
329
1006
Y06
ICPC
Prostate symptom/complaint
4.0
88.5
277
768
PJD64
NOMESCO Finland
Laparoscopic dissection of iliac lymph nodes
7.4
81.9
122
174
3031
Kela drug reimbursment
Apalutamidi
34.9
80.5
51
15
1528, ,
Kela drug reimbursment
34.2
78.4
50
15
YX9AD
NOMESCO Finland
Other CT eamination for dose design of radiotherapy
5.6
76.7
151
286
L02BB05
ATC
apalutamide; oral
30.7
72.9
48
16
ZX080
NOMESCO Finland
Image guided radiotherapy
6.9
70.6
112
171
R33
ICD-10 Finland
Retention of urine
2.7
66.4
439
1892
WF090
NOMESCO Finland
Profylactic radiotherapy
8.6
66.3
86
104
KE1BE
NOMESCO Finland
Rectal ultrasound examinaiton of prostata
2.5
65.3
548
2647
KEC01
NOMESCO Finland
Percutaneous endoscopic radical prostatectomy
4.2
63.5
181
465
KBV15
NOMESCO Finland
Cystoscopic change of ureteral stent
12.8
63.4
62
50
WB223
NOMESCO Finland
Demanding adjuvant hormone therapy of malignancy
11.8
63.1
65
57
XJH00
NOMESCO Finland
Transanal ultrasonography
2.8
62.6
390
1626
J01MA02
ATC
ciprofloxacin; systemic
2.2
61.3
1030
6620
K62.7
ICD-10 Finland
Radiation proctitis
8.4
60.5
80
99
XX7AT
NOMESCO Finland
Radiation therapy with Radium-223
311.9
59.7
60
*
A49.9
ICD-10 Finland
Bacterial infection, unspecified
2.6
58.7
429
1930
KH1BT
NOMESCO Finland
Urinary tract cathetrisation with X-ray guidance
6.9
57.6
90
135
ZXC96
NOMESCO Finland
Robot assisted procedure
4.2
56.9
159
402
SPAT1254
SPAT
Administration of medicine
2.5
56.5
425
1936
ZX120
NOMESCO Finland
Intravenous
2.9
55.6
304
1178
KH1FT
NOMESCO Finland
Exchange of urinary catheter with radiological guidance
10.6
55.5
61
59
H02AB06
ATC
prednisolone; systemic
2.1
53.6
1056
7082
WB203
NOMESCO Finland
Simple adjuvant hormone therapy of malignancy
21.5
53.3
40
19
WF003
NOMESCO Finland
Adjuvant radiotherapy
4.6
52.9
130
297
WW500
NOMESCO Finland
Blood transfusion
3.8
52.0
169
476
ZX112, ,
SPAT
17.2
50.6
42
25
A02BC02
ATC
pantoprazole; systemic
2.2
50.3
1417
10746
KEB00
NOMESCO Finland
Biopsy of prostate
4.9
47.6
109
235
L03AA02
ATC
filgrastim; parenteral
4.5
47.0
117
270
XX7LT
NOMESCO Finland
Lutetium-177-PSMA treatment
125.6
46.0
49
*
H02AB07
ATC
prednisone; oral
2.5
45.1
337
1516
ZX013
NOMESCO Finland
Radiotherapy with large shaped fields - SSD therapy
8.8
44.5
56
65
TKE10
NOMESCO Finland
Puncture of prostate
5.8
40.7
75
133
G04CA02
ATC
tamsulosin; oral
1.9
40.2
1112
8058
KH1YT
NOMESCO Finland
Percutaneous implantation of endoprothesis with radiological guidance
10.7
39.4
43
41
TNX00
NOMESCO Finland
Puncture and needle biopsy of soft tissue, unspecified region
6.2
38.9
67
111
R31
ICD-10 Finland
Unspecified haematuria
2.1
37.3
429
2297
UKC02
NOMESCO Finland
Cystoscopy
1.9
35.5
610
3754
KFC10
NOMESCO Finland
Bilateral orchiectomy
10.2
35.4
40
40
WZC20
NOMESCO Finland
Multidisciplinary treatment meeting
2.9
34.8
170
614
SPAT1088
SPAT
Blood transfusion
8.2
34.7
46
57
KEC00
NOMESCO Finland
Retropubic radical prostatectomy
3.7
34.5
112
314
NA7DG
NOMESCO Finland
Spine and spinal cord very extensive MRI examination with high intensity magnet
7.2
34.4
51
72
WF099
NOMESCO Finland
Other radiotherapy
9.1
34.3
42
47
1CD04, ,
NOMESCO Finland
343.1
34.0
34
*
308
Kela drug reimbursment
Alprostadil, sildenafil and combination product containing aviptadil and phentolamine
3.4
33.1
123
377
WF029
NOMESCO Finland
Radiotherapy of local residive tumor
6.5
33.0
54
85
TKC10
NOMESCO Finland
Percutaneous puncture of bladder
4.4
32.5
82
191
YX9BD
NOMESCO Finland
Other extensive CT eamination for dose design of radiotherapy
7.8
32.4
45
59
Z03.1
ICD-10 Finland
Observation for suspected malignant neoplasm
3.8
31.4
99
272
N02BE01
ATC
paracetamol; systemic, rectal
2.3
30.8
1712
14904
EB1HA
NOMESCO Finland
Panorama tomography of teeth and jaws or similar X-ray examination
1.7
28.9
777
5399
5BX04, ,
NOMESCO Finland
49.4
28.4
34
7
KE1BG
NOMESCO Finland
MRI of prostate
4.6
28.2
68
153
TKC20
NOMESCO Finland
Catheterisation of bladder
2.2
27.9
252
1216
L02BB01
ATC
flutamide; oral
10.9
27.8
30
28
A55
ICPC
General and Unspecified, Local injection/infiltration
6.4
27.0
45
72
PJD44
NOMESCO Finland
Excision of iliac lymph nodes
5.7
27.0
50
89
TKC22
NOMESCO Finland
Catheterisation instruction
3.0
27.0
122
421
ECB20
NOMESCO Finland
Oral alveoplasty
5.3
26.8
54
104
JN2CG
NOMESCO Finland
Extensive MRI examination of lower part of abdoment with high intensity magnet
4.4
26.4
67
157
A28
ICPC
Limited function/disability NOS
1.8
26.1
460
2810
WPA10
NOMESCO Finland
Proactive palliative care treatment plan
6.7
26.0
41
62
EB1BI
NOMESCO Finland
Cone beam imaging of teeth and jaws (1–2 quarters)
5.0
25.9
56
115
KA3EB
NOMESCO Finland
Antegrade pyelography
6.8
25.5
40
60
ZX050
NOMESCO Finland
Stereotactic radiotherapy
5.5
25.3
49
91
SPAT1203
SPAT
Injection therapy, other than intramuscular or subcutaneous
3.1
25.0
110
374
ZXC20
NOMESCO Finland
Use of chemical agents
3.5
23.8
84
249
N42.9
ICD-10 Finland
Disorder of prostate, unspecified
3.4
23.7
88
270
A98
ICPC
Health maint/preventive medicine
2.4
23.1
1787
16211
N10
ICD-10 Finland
Acute tubulo-interstitial nephritis
1.9
23.0
322
1822
JN4CD
NOMESCO Finland
Very extensive body CT
2.7
22.9
132
519
B01AB10
ATC
tinzaparin; parenteral
2.1
22.8
234
1184
166
Kela drug reimbursment
Dalteparin and tinzaparin (treatment for more than 6 months)
5.5
22.5
43
79
KE1CG
NOMESCO Finland
Extensive MRI of prostate
5.1
21.9
46
92
XX7JT
NOMESCO Finland
Somatostatin isotope ablative therapy
25.4
21.8
30
12
J01MA12
ATC
levofloxacin; systemic
1.7
21.6
470
3033
L95
ICPC
Osteoporosis
4.6
21.5
51
113
K52.0
ICD-10 Finland
Gastroenteritis and colitis due to radiation
8.3
21.4
28
34
B03XA02
ATC
darbepoetin alfa; parenteral
3.2
21.3
84
267
A50
ICPC
General and Unspecified, Medication/prescr/renewal
2.9
21.0
99
350
N39.0
ICD-10 Finland
Urinary tract infection, site not specified
2.0
20.9
271
1490
WD125
NOMESCO Finland
Demanding cystostatic therapy of methastized malignancy
2.5
20.6
138
583
WVA30
NOMESCO Finland
Intramuscular and subcutaneous injection
7.9
20.4
28
36
SPAT1167
SPAT
Insertion of urinary catheter
2.5
20.4
128
524
WVA20, ,
SPAT
3.6
20.4
69
199
R50.9
ICD-10 Finland
Fever, unspecified
1.8
20.1
342
2050
KBV02
NOMESCO Finland
Cystoscopic insertion of stent into ureter
3.1
20.1
84
277
YG1BD
NOMESCO Finland
Extensive CT examination of thorax for dose design of radiotherapy
4.1
19.3
53
132
C77.9
ICD-10 Finland
Secondary and unspecified malignant neoplasm: Lymph node, unspecified
31.6
19.3
25
8
WB221
NOMESCO Finland
Demanding neoadjuvant hormone therapy of malignancy
8.0
19.2
26
33
J01EA01
ATC
trimethoprim; systemic
1.8
19.1
322
1924
N02AJ06
ATC
codeine and paracetamol; systemic
1.6
18.6
749
5589
KH1AE
NOMESCO Finland
Urinary tract ultrasound examination
2.0
18.5
209
1093
G04BD12
ATC
mirabegron; oral
1.8
18.5
302
1786
OAB42
NOMESCO Finland
Guidance related to known health problem
6.5
18.4
30
47
R06AE07
ATC
cetirizine; oral
1.6
18.2
576
4063
KH1AT
NOMESCO Finland
Urinary tract cathetrisation with ultrasound guidance
7.3
17.8
26
36
NK6SN
NOMESCO Finland
Bone SPECT
20.3
17.7
26
13
D70.82
ICD-10 Finland
Drug-induced neutropenia
4.3
17.4
45
107
S50
ICPC
Skin, Medication/prescr/renewal
5.5
17.1
33
61
Z51.0
ICD-10 Finland
Radiotherapy session
3.9
17.1
51
135
YN1AD
NOMESCO Finland
CT examination of extremities for dose design of radiotherapy
22.1
16.9
24
11
PH2AE
NOMESCO Finland
Ultrasound examination of lower leg veins
1.8
16.2
250
1450
WZB00
NOMESCO Finland
Telephone prescription or other care instructions
1.6
16.0
440
2988
A06AD11
ATC
lactulose; oral
1.7
16.0
348
2227
J01DB01
ATC
cefalexin; oral
1.6
15.9
1494
13176
SAA03
NOMESCO Finland
Extended examination of mouth
1.5
15.8
589
4287
GD1AA
NOMESCO Finland
Thorax X-ray examination
1.5
15.6
1032
8439
KE1DG
NOMESCO Finland
Very extensive MRI of prostate
3.5
15.6
53
154
TPH04
NOMESCO Finland
Cathetrisation of vein
1.6
15.6
475
3303
JN3BD
NOMESCO Finland
Extensive abdominal CT
1.9
15.5
220
1243
KE002
NOMESCO Finland
Radical radiotherapy of prostata and seminal vesicles
5.8
15.4
28
49
M49.5*C79.5
ICD-10 Finland
Metastatic fracture of vertebra
13.2
15.2
26
20
G04BE03
ATC
sildenafil; oral
2.8
15.1
75
273
EB1AI
NOMESCO Finland
Cone beam imaging of teeth and jaws (one quarter)
4.0
15.1
42
106
Y50
ICPC
Male Genital, Medication/prescr/renewal
11.9
15.1
27
23
C78.7
ICD-10 Finland
Secondary malignant neoplasm of liver and intrahepatic bile duct
2.7
15.1
80
302
TQX05
NOMESCO Finland
Skin puncture, unspecified location
14.1
15.0
25
18
U08
ICPC
Urinary retention
2.5
14.8
95
394
Y78
ICPC
Malign neopl male genital other
13.3
14.7
25
19
KDV12
NOMESCO Finland
Urethroscopic internal urethrotomy
3.2
14.4
56
177
KC1GB
NOMESCO Finland
Cystography with X-ray
3.2
14.3
56
178
D64.9
ICD-10 Finland
Anaemia, unspecified
1.7
13.8
285
1793
KA1AE
NOMESCO Finland
Kidney ultrasound examination
2.5
13.7
84
341
Z3231
NOMESCO Finland
Registered nurse
1.5
13.6
550
4046
EBA10
NOMESCO Finland
Operative extraction of tooth
1.9
13.6
169
912
U28
ICPC
Limited function/disability (U)
3.5
13.5
46
134
ZX020
NOMESCO Finland
HDR radiotherapy within tissue
10.1
13.5
26
26
C03CA01
ATC
furosemide; systemic
1.4
13.1
749
5890
R86.1
ICD-10 Finland
Abnormal findings in specimens from male genital organs, abnormal level of hormones
6.0
13.1
23
39
N30.4
ICD-10 Finland
Irradiation cystitis
11.0
13.0
24
22
8000/3-C61.9
ICD-O-3
Neoplasm, malignant of prostate gland
22.7
12.9
18
8
130
Kela drug reimbursment
Malignant tumour
0.4
12.6
77
1712
JN2DM
NOMESCO Finland
Lower part of abdomen very extensive MRI examination with Tesla magnet
10.1
12.5
24
24
WPB10
NOMESCO Finland
Making a convalescent care decision
10.6
12.2
23
22
D63.0
ICD-10 Finland
Anaemia in neoplastic disease
26.9
12.0
16
6
M05BA08
ATC
zoledronic acid; parenteral
47.0
11.9
14
*
A07EA02
ATC
hydrocortisone; rectal
3.0
11.7
50
168
B01AB05
ATC
enoxaparin; parenteral
1.4
11.6
616
4751
L02BB06
ATC
darolutamide; oral
13.7
11.5
19
14
-55
ICPC
Local injection/infiltration
4.5
11.4
27
60
YG1AD
NOMESCO Finland
CT examination of thorax for dose design of radiotherapy
3.9
11.4
33
86
M01AE01
ATC
ibuprofen; systemic, rectal
1.5
11.3
1507
13629
SPAT1154
SPAT
Insertion or removal of subcutaneous medicine capsule
10.6
11.3
21
20
SPAT1109
SPAT
Analgesia with portable analgesic pump
4.4
11.2
28
65
EB1CI
NOMESCO Finland
Cone beam imaging of teeth and jaws (3-4 quarters)
4.0
11.2
31
78
U13
ICPC
Bladder symptom/complaint other
2.7
11.2
60
228
N39.3
ICD-10 Finland
Stress incontinence
3.2
11.0
42
132
XX9AQ
NOMESCO Finland
Supplementary SPECT-CT or additional scan
12.0
10.8
19
16
WX408
NOMESCO Finland
General anesthesy, balanced
1.4
10.7
505
3801
XX3AT
NOMESCO Finland
Other labeling with ultrasound guidance
4.6
10.7
25
55
A04AA55
ATC
palonosetron, combinations; systemic
3.1
10.6
43
140
NA3DG
NOMESCO Finland
Lumbar spine very extensive MRI examination with high intensity magnet
4.5
10.5
25
56
NF3AA
NOMESCO Finland
Femur X-ray examination
2.8
10.3
49
175
WC205
NOMESCO Finland
Simple therapy of local tumor recidive with hormone
40.3
10.0
12
*
EDW99
NOMESCO Finland
Other operation on mandible
12.2
9.8
17
14
Z08.1
ICD-10 Finland
Follow-up examination after radiotherapy for malignant neoplasm
4.9
9.8
21
43
K62.8
ICD-10 Finland
Other specified diseases of anus and rectum
4.0
9.8
27
68
JN3CD
NOMESCO Finland
Abdominal CT examination both without and with contrast
2.1
9.7
97
485
C78.0
ICD-10 Finland
Secondary malignant neoplasm of lung
2.6
9.6
55
217
A49.8
ICD-10 Finland
Other bacterial infections of unspecified site
3.7
9.4
29
79
ZX100
NOMESCO Finland
Oral
2.9
9.4
44
156
C79.1
ICD-10 Finland
Secondary malignant neoplasm of bladder and other and unspecified urinary organs
+∞
9.4
9
*
3036, ,
Kela drug reimbursment
21.8
9.3
13
6
1525, ,
Kela drug reimbursment
21.8
9.3
13
6
U50
ICPC
Urological, Medication/prescr/renewal
21.8
9.3
13
6
SPAT1245
SPAT
Provision of support and information to patient’s family members
1.9
9.3
111
591
SPAT1263
SPAT
Sampling
1.4
9.3
722
5892
-50
ICPC
Medication/prescr/renewal
2.1
9.2
92
460
JN3AD
NOMESCO Finland
Abdominal CT examination
1.6
9.2
231
1522
U04
ICPC
Incontinence urine
2.0
9.1
104
547
NE1AA
NOMESCO Finland
Pelvis X-ray examination
1.7
9.0
157
941
L28
ICPC
Limited function/disability (L)
1.5
9.0
353
2558
K62.5
ICD-10 Finland
Haemorrhage of anus and rectum
1.9
8.7
111
606
N02AA01
ATC
morphine; systemic, rectal
2.5
8.7
54
222
5BA08, ,
NOMESCO Finland
6.6
8.7
21
32
KCW02
NOMESCO Finland
Lavation of bladder for coagulated blood
2.6
8.6
48
187
XF600
NOMESCO Finland
Bloodpressure measurement
1.8
8.5
133
773
KCW96
NOMESCO Finland
Other operations on bladder
4.0
8.3
23
58
HB000
NOMESCO Finland
Profylactic radiotherapy of mammary gland
9.5
8.3
16
17
SPAT1255
SPAT
Intravenous administration of medicine
1.7
8.2
154
941
B02AA02
ATC
tranexamic acid; systemic
1.8
8.2
115
646
K10.20
ICD-10 Finland
Osteomyelitis (neonatal) of jaw (acute)(chronic)(suppurative)
11.7
8.1
14
12
WX110
NOMESCO Finland
Infiltration anesthesia
1.3
8.0
1142
10098
KDW96
NOMESCO Finland
Other operations on urethra
7.3
8.0
18
25
L01XX11
ATC
estramustine; systemic
7.3
8.0
18
25
T88.7
ICD-10 Finland
Unspecified adverse effect of drug or medicament
3.3
7.8
29
90
U06
ICPC
Haematuria
2.0
7.8
84
434
K10.25
ICD-10 Finland
Sequences of jawbones
5.9
7.7
20
34
Z43.5
ICD-10 Finland
Attention to cystostomy
3.4
7.7
27
81
KED22
NOMESCO Finland
Transurethral resection of prostate
1.5
7.6
247
1721
SPAT1230
SPAT
Aid fitting and borrowing and monitoring of use
1.5
7.5
296
2140
YN1BD
NOMESCO Finland
Extensive CT examination of extremities for dose design of radiotherapy
10.1
7.5
14
14
GD1QA
NOMESCO Finland
Supine thorax X-ray examination
1.4
7.5
423
3258
TQW40, ,
SPAT
0.4
7.5
32
828
SAA02
NOMESCO Finland
Basic examination of mouth
1.3
7.5
927
8009
JAP01
NOMESCO Finland
Laparoscopic freeing of adhesions in the peritoneal cavity
3.8
7.4
22
59
ZXF10
NOMESCO Finland
Interruption caused by technical failure of equipment
8.4
7.3
15
18
C61, C798,
ICD-10 Finland
+∞
7.3
7
*
C61, C795,
ICD-10 Finland
+∞
7.3
7
*
WPA15
NOMESCO Finland
Palliative care consultation with the patient and loved ones
5.8
7.2
19
33
WX290
NOMESCO Finland
Other blockage of nerve
1.3
7.2
589
4801
A29
ICPC
General symptom/complaint other
1.5
7.2
237
1655
ZXF99
NOMESCO Finland
Other r3eason to interrupt procedure
4.5
7.2
17
38
R60.0
ICD-10 Finland
Localized oedema
1.5
7.2
233
1623
WB211
NOMESCO Finland
Neoadjuvant hormone therapy of malignancy
30.1
7.1
9
*
J01CR02
ATC
amoxicillin and beta-lactamase inhibitor; systemic
1.3
7.1
791
6719
SPAT1222
SPAT
Counselling/guidance promoting independent living
1.4
7.1
291
2118
WGA10
NOMESCO Finland
Measurement of pain intensity
20.1
7.1
10
5
R39.1
ICD-10 Finland
Other difficulties with micturition
1.9
7.1
88
477
JN2BG
NOMESCO Finland
MRI examination of lower part of abdoment with high intensity magnet
6.0
7.1
18
30
C79.30
ICD-10 Finland
Secondary malignant tumor of the cerebrum
3.1
6.9
28
92
NA2BG
NOMESCO Finland
Thoracal spine MRI examination with high intensity magnet
2.6
6.8
38
149
G04BE01
ATC
alprostadil; parenteral, urethral
1.9
6.7
77
406
KDE20
NOMESCO Finland
Removal of foreign body from urethra
2.5
6.7
39
156
G04BD08
ATC
solifenacin; oral
1.6
6.7
137
859
2AE02, ,
NOMESCO Finland
22.6
6.7
9
*
WB201
NOMESCO Finland
Simple neoadjuvant hormone therapy of malignancy
12.3
6.6
11
9
EBA15
NOMESCO Finland
Extraction of multiple teeth
1.8
6.6
93
526
A03
ICPC
Fever
1.5
6.5
189
1286
R2130
NOMESCO Finland
Counselling and guidance which enhance independent living
1.6
6.5
157
1025
WPA13
NOMESCO Finland
Palliative consultation
5.7
6.4
17
30
JR2PR, ,
NOMESCO Finland
70.1
6.4
7
*
L02BX04
ATC
relugolix; oral
70.1
6.4
7
*
AA3AI
NOMESCO Finland
Cone beam CT of facial bones
3.8
6.4
19
51
U29
ICPC
Urinary symptom/complaint other
2.1
6.3
60
296
Z2221
NOMESCO Finland
Medical doctor
1.3
6.3
430
3401
Y99
ICPC
Genital disease male other
8.2
6.3
13
16
U99
ICPC
Urinary disease other
3.0
6.3
27
92
XX7KT
NOMESCO Finland
Radiosamarium therapy
+∞
6.3
6
*
JN5AN
NOMESCO Finland
Total body isotope imaging
26.8
6.2
8
*
JN2CM
NOMESCO Finland
Lower part of abdomen extensive MRI examination with Tesla magnet
3.4
6.1
21
62
A21
ICPC
Risk factor for malignancy
7.7
6.1
13
17
KCE00
NOMESCO Finland
Cystolithotomy
12.6
6.1
10
8
EDA10
NOMESCO Finland
Biopsy of mandible
10.0
6.0
11
11
LabWAS
↥OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
1111
1950
12.11
307.65
2.8
2.0
2.46
12.95
nmol/l
258.50
912
1671
1587
9011
5.34
194.24
16.1
6.8
9.89
13.48
umol/l
46.56
1567
8610
1168
5444
3.91
186.93
10.8
3.4
2.33
2.33
mmol/l
0.22
1101
4702
1837
12772
10.59
151.44
20.2
8.2
103.60
80.78
u/l
19.61
1812
12051
1463
8915
3.67
135.26
12.9
7.7
1.20
1.20
mmol/l
1.88
1257
7554
1622
10841
4.15
123.75
6.0
4.5
264.42
998.75
e6/l
0.65
24
200
1838
13565
8.85
121.10
19.6
5.3
34.61
3.14
ug/l
17.65
1784
12030
1462
9307
3.37
117.05
18.2
8.9
4.24
4.51
e9/l
3.79
1343
8074
1287
8141
2.75
94.05
9.4
6.8
1.21
1.20
mmol/l
6.77
1226
7415
1527
10873
2.96
82.88
9.4
4.7
20.57
22.05
%
3.05
1183
5840
1198
7659
2.49
79.87
5.1
3.3
1.99
0.76
ug/l
21.79
987
5611
575
2649
2.67
77.50
6.7
4.1
277.13
239.90
u/l
4.00
555
2508
1199
7834
2.41
73.58
6.8
5.5
33.65
34.32
g/l
3.75
1145
7270
992
6003
2.35
72.28
4.6
3.7
139.25
101.80
e6/l
0.51
855
4813
637
3184
2.50
71.50
5.9
3.3
2.46
2.45
mmol/l
0.59
604
2772
895
5415
2.22
62.39
4.4
3.5
0.41
0.47
e6/l
0.26
767
4277
1018
6532
2.19
60.62
5.2
4.1
116.89
106.19
e6/l
0.10
872
5036
1827
15307
4.80
59.40
27.7
19.0
32.16
30.24
mg/l
1.51
1684
12742
729
4245
2.15
54.01
3.3
2.8
2.94
2.88
e6/l
0.09
673
3826
1110
7824
1.99
46.23
6.4
6.2
22.46
24.92
%
10.34
1041
7308
1121
8003
1.96
44.11
3.4
2.9
—
—
—
0
0
591
3391
2.07
43.68
1.9
1.9
—
—
—
0
0
561
3176
2.08
42.86
4.1
3.4
0.65
0.63
e6/l
0.08
375
1921
1843
16180
4.26
42.01
21.6
11.8
23.57
27.44
u/l
7.28
1808
15483
1869
16591
5.35
41.44
43.5
27.7
37.40
40.18
%
62.68
1757
15236
1869
16596
5.34
41.31
43.7
27.5
231.46
224.80
e9/l
4.30
1839
16110
1869
16598
5.33
41.26
43.6
27.5
4.14
4.47
e12/l
123.50
1835
16032
1869
16598
5.33
41.26
43.7
27.5
6.74
7.07
e9/l
5.25
1837
16033
1869
16602
5.32
41.16
43.9
27.7
124.63
136.36
g/l
156.27
1848
16313
1074
7688
1.90
40.47
6.3
6.0
61.87
59.21
%
8.93
1014
7177
1070
7684
1.88
39.55
6.1
6.1
2.70
2.92
%
1.77
998
7161
318
1486
2.37
38.73
7.4
4.7
1.21
1.21
mmol/l
0.08
299
1322
1847
16374
4.16
38.55
30.7
23.0
4.03
4.04
mmol/l
1.26
1820
15987
1845
16346
4.10
38.52
30.2
22.7
139.29
139.63
mmol/l
6.84
1819
15974
1700
14516
2.46
36.33
32.3
18.1
76.52
72.82
ml/min/173m2
13.45
1582
12198
1361
10735
1.91
35.68
5.2
5.5
6.94
6.99
mmol/l
0.32
1314
10193
1274
9840
1.87
35.65
17.3
20.8
1.26
1.44
inr
10.47
387
2794
675
4351
1.85
33.64
3.1
2.7
—
—
—
0
0
553
3348
1.91
33.51
3.8
3.2
1.00
0.91
e6/l
0.40
364
2075
1107
8422
1.74
30.10
6.3
5.8
0.17
0.21
e9/l
10.83
933
7325
947
7035
1.68
26.91
16.9
11.1
0.01
0.00
e9/l
0.18
791
5755
723
5004
1.71
26.76
6.1
3.4
37.69
41.97
u/l
0.46
696
4735
390
2315
1.86
24.07
1.9
1.8
—
—
—
0
0
386
2299
1.85
23.52
1.9
1.9
—
—
—
0
0
695
4895
1.66
23.28
2.0
2.2
3.09
2.98
mg/l
0.65
602
4154
217
1074
2.15
22.40
1.9
1.9
2.60
2.33
ug/l
0.07
195
938
490
3196
1.72
21.67
2.3
2.8
12.08
12.50
umol/l
0.61
466
2987
493
3231
1.71
21.38
3.1
3.4
0.82
0.81
mmol/l
0.52
476
3033
463
3005
1.71
20.72
2.1
2.8
2.07
2.21
g/l
6.24
430
2797
847
6472
1.55
19.06
3.4
3.3
1819.92
1861.47
ng/l
0.10
763
5735
436
2874
1.67
18.09
2.2
2.9
23.45
22.94
%
0.28
375
2450
235
1294
1.93
17.94
1.7
1.7
—
—
—
0
0
617
4467
1.56
17.24
5.3
4.4
87.09
79.32
%
11.01
609
4386
224
1242
1.91
16.71
1.6
1.5
—
—
—
0
0
1114
9187
1.50
16.60
3.7
3.4
54.91
64.40
u/l
2.64
1018
8369
802
6208
1.50
16.14
2.5
3.0
464.48
196.23
ug/l
13.69
729
5632
175
903
2.03
16.05
2.0
2.0
—
—
—
0
0
960
7792
1.46
14.75
4.1
3.6
0.00
0.00
estimate
-0.00
222
1450
1447
12754
1.54
14.59
37.1
22.1
15.60
15.55
%
0.13
1436
12518
944
7655
1.46
14.47
5.4
4.8
0.00
0.00
estimate
-0.00
233
1552
325
2095
1.66
14.39
2.9
4.3
20.45
28.06
ug/l
0.35
265
1791
159
836
1.98
13.82
1.9
1.8
—
—
—
0
0
841
6844
1.41
11.76
2.3
2.1
—
—
—
0
0
930
7738
1.39
11.22
4.1
3.6
0.01
0.01
estimate
0.12
248
1646
891
7363
1.39
11.19
4.1
4.3
75.02
62.18
ng/l
0.18
776
6001
85
390
2.23
10.59
1.7
3.9
2.72
1.82
%
1.12
71
342
61
246
2.53
10.15
2.2
1.2
—
—
—
0
0
293
2004
1.55
9.90
3.1
3.0
225.49
244.74
ng/l
0.26
275
1844
601
4729
1.39
9.77
1.8
1.6
17.11
18.84
nmol/l
2.32
523
4037
678
5467
1.37
9.42
2.5
2.7
51.86
75.49
u/l
0.97
637
5069
381
2784
1.46
9.30
2.7
2.4
1.80
1.73
%
0.74
347
2448
216
1407
1.60
8.99
2.4
4.1
1.76
0.72
%
1.73
114
548
290
2052
1.49
8.28
3.3
4.1
5.59
5.83
kpa
4.32
283
1983
97
519
1.92
8.08
1.2
1.7
—
—
—
0
0
289
2060
1.47
7.94
3.3
4.1
1.45
1.85
mmol/l
1.10
231
1710
313
4167
0.70
7.39
1.6
1.7
1.52
1.30
mmol/l
3.04
248
3401
709
5928
1.31
7.22
4.5
3.9
—
—
—
0
0
293
2132
1.44
7.20
3.2
2.5
68.48
67.16
e9/l
0.26
230
1649
209
1430
1.52
6.99
1.5
1.7
—
—
—
0
0
475
3816
1.32
6.29
4.0
4.2
332.14
694.04
ng/l
0.90
423
3403
88
498
1.80
6.21
1.3
1.7
—
—
—
0
0
269
1984
1.41
6.10
3.5
3.0
7.09
11.15
umol/l
3.90
244
1797
522
6274
0.77
5.98
3.2
3.3
7.46
8.11
mmol/l
3.81
412
5184
52
251
2.10
5.85
1.8
4.1
63.43
57.28
%
1.15
40
206
74
411
1.83
5.58
1.6
1.3
—
—
—
0
0
74
411
1.83
5.58
1.6
1.3
—
—
—
0
0
100
609
1.68
5.49
1.2
1.3
—
—
—
0
0
65
349
1.89
5.45
1.2
1.6
—
—
—
0
0
65
349
1.89
5.45
1.2
1.6
—
—
—
0
0
353
2771
1.34
5.41
4.6
6.9
1.03
1.03
mmol/l
0.01
332
2597
82
475
1.76
5.40
3.7
3.7
7.14
7.70
mmol/l
1.24
82
461
208
1506
1.43
5.23
2.4
2.5
31.72
41.53
u/l
1.33
179
1293
528
6236
0.79
5.03
3.1
3.4
415.77
287.87
mg/l
0.30
367
4369
561
6578
0.79
5.01
3.8
4.0
8.13
11.01
mg/mmol
1.30
374
4515
651
5617
1.24
4.62
2.0
2.1
81.97
76.35
nmol/l
4.89
573
4858
282
2198
1.33
4.51
5.6
7.8
11.42
11.57
mmol/l
0.11
264
2081
28
117
2.41
4.48
1.7
3.1
—
—
—
0
0
45
234
1.95
4.22
1.4
1.7
—
—
—
0
0
26
113
2.32
3.85
1.2
1.9
—
—
—
0
0
26
113
2.32
3.85
1.2
1.9
—
—
—
0
0
99
1451
0.67
3.84
1.7
1.7
1.57
1.73
%
1.70
83
1187
520
4455
1.23
3.82
4.4
3.9
0.00
0.00
estimate
0.21
208
1401
44
236
1.88
3.80
1.4
1.5
—
—
—
0
0
397
3312
1.25
3.72
1.5
1.7
2.34
1.64
mg/l
1.95
329
2642
63
380
1.68
3.69
1.4
1.7
—
—
—
0
0
44
240
1.85
3.62
1.4
1.5
—
—
—
0
0
44
242
1.84
3.54
1.4
1.5
—
—
—
0
0
79
512
1.57
3.49
2.8
2.6
15.25
15.99
%
1.11
41
286
136
1845
0.72
3.46
1.2
1.2
14.76
16.72
u/ml
0.08
35
625
449
5203
0.82
3.29
2.8
3.2
5136.13
6076.63
umol/l
0.09
371
4449
156
1170
1.36
3.25
1.4
1.7
1.86
1.52
g/l
2.83
125
1003
8
233
0.34
3.18
1.0
1.1
—
—
—
0
0
211
1662
1.30
3.15
2.7
3.3
4.13
4.55
kpa
2.50
201
1602
180
2306
0.76
3.14
1.4
1.6
2.64
3.06
g/l
1.44
97
1398
42
240
1.77
3.03
1.4
1.5
—
—
—
0
0
42
242
1.75
2.95
1.4
1.5
—
—
—
0
0
42
242
1.75
2.95
1.4
1.5
—
—
—
0
0
256
2085
1.26
2.94
3.7
3.9
—
—
—
0
0
188
2372
0.77
2.93
1.2
1.2
0.94
2.25
u/ml
3.94
34
583
55
343
1.62
2.90
1.2
1.5
—
—
—
0
0
32
172
1.88
2.82
1.3
1.7
—
—
—
0
0
59
378
1.58
2.80
1.2
1.5
—
—
—
0
0
25
124
2.03
2.76
1.2
1.6
—
—
—
0
0
(3020427) Coagulation factor X inhibitor [Units/volume] in Platelet poor plasma by Coagulation assay
125
934
1.36
2.71
2.8
2.8
0.36
0.32
u/ml
0.62
75
520
1236
11664
1.17
2.68
3.2
4.1
20.80
13.77
mm/h
21.15
1125
10671
185
1470
1.29
2.61
3.1
3.8
1.69
1.76
mmol/l
0.09
129
1047
834
7652
1.16
2.61
2.0
2.1
88.96
90.37
pmol/l
0.37
502
4405
49
308
1.61
2.54
1.2
1.5
—
—
—
0
0
48
303
1.60
2.45
1.4
1.6
—
—
—
0
0
956
10222
0.87
2.37
3.1
3.1
15.13
15.05
pmol/l
0.40
837
8970
49
315
1.57
2.34
1.3
1.5
—
—
—
0
0
27
147
1.85
2.33
1.3
1.8
1.80
1.35
u/field
—
5
51
158
1974
0.78
2.30
1.1
1.2
28.99
41.73
iu/ml
0.85
47
549
58
389
1.51
2.30
1.4
1.4
—
—
—
0
0
39
238
1.65
2.29
1.2
1.5
—
—
—
0
0
39
238
1.65
2.29
1.2
1.5
—
—
—
0
0
27
148
1.84
2.29
1.2
1.6
—
—
—
0
0
190
1553
1.25
2.16
3.2
3.9
4.95
5.10
kpa
1.69
179
1470
73
520
1.42
2.15
2.7
2.1
123.09
128.55
g/l
1.21
57
381
28
159
1.77
2.14
1.3
1.4
—
—
—
0
0
49
324
1.53
2.10
3.3
3.6
60.00
58.67
%
0.31
49
324
23
125
1.85
2.02
1.3
1.6
—
—
—
0
0
5
144
0.35
2.01
1.0
1.1
—
—
—
0
0
18
90
2.01
2.00
1.3
2.1
—
—
—
0
0
17
322
0.52
1.95
1.1
1.4
11.82
36.95
e6/l
0.68
11
256
17
321
0.53
1.93
1.2
1.4
23.42
1256.89
e6/l
1.83
12
267
35
222
1.59
1.82
1.2
1.7
—
—
—
0
0
116
914
1.29
1.82
3.0
4.4
24.49
24.68
mmol/l
0.31
104
838
261
2244
1.19
1.82
4.4
5.0
32.03
32.48
%
0.28
175
1518
50
344
1.47
1.81
1.2
1.3
—
—
—
0
0
36
232
1.56
1.76
1.2
1.7
—
—
—
0
0
17
88
1.94
1.75
1.3
2.1
—
—
—
0
0
17
88
1.94
1.75
1.3
2.1
—
—
—
0
0
28
170
1.66
1.74
1.5
1.6
—
—
—
0
0
438
3935
1.15
1.74
2.0
1.8
1193.58
1152.41
nmol/l
0.36
335
2965
611
5611
1.13
1.73
2.6
2.2
213.49
265.04
u/l
0.74
577
5242
48
331
1.46
1.73
5.3
6.6
13.13
11.83
mg/l
0.92
42
309
1521
14750
1.15
1.72
6.4
7.0
41.70
41.49
mmol/mol
0.21
1372
13423
28
444
0.63
1.71
1.0
1.0
—
—
—
0
0
0
48
0.00
1.69
0.0
1.3
—
—
—
0
0
97
1233
0.78
1.68
1.9
2.6
9.67
10.93
g/l
2.48
84
1124
20
343
0.58
1.67
1.3
1.3
—
—
—
0
0
444
4004
1.14
1.66
2.2
1.8
413.65
27411415.57
pmol/l
3.05
373
3287
42
607
0.69
1.66
2.1
1.9
—
—
—
0
0
18
309
0.58
1.53
1.2
1.5
—
—
—
0
0
39
268
1.46
1.47
2.2
2.2
19.75
25.02
mg/l
0.41
12
57
380
3421
1.14
1.46
2.3
2.0
30.39
30.36
s
0.03
368
3322
31
203
1.54
1.46
1.2
1.7
—
—
—
0
0
31
203
1.54
1.46
1.2
1.7
—
—
—
0
0
31
203
1.54
1.46
1.2
1.7
—
—
—
0
0
19
313
0.60
1.40
1.5
1.5
4.64
3.29
mg/l
0.34
19
232
102
1257
0.80
1.40
2.3
2.3
161.24
195.87
ug/g
0.49
77
1004
7
29
2.42
1.39
1.9
2.3
—
—
—
0
0
14
74
1.90
1.39
1.4
1.4
—
—
—
0
0
25
158
1.59
1.37
1.5
1.5
—
—
—
0
0
44
315
1.41
1.35
3.3
3.3
4.44
4.44
e9/l
0.00
44
315
0
40
0.00
1.32
0.0
10.8
—
5.56
—
0
40
171
1462
1.19
1.32
5.4
3.0
60.68
59.20
ml/min/173m2
0.22
78
630
11
207
0.53
1.31
1.4
2.2
754.00
661.76
ml
—
6
120
149
1261
1.20
1.29
2.4
4.7
119.32
112.57
ng/l
0.21
128
1092
202
2315
0.86
1.28
9.8
8.4
—
—
—
0
0
72
563
1.29
1.27
1.3
1.6
—
—
—
0
0
24
363
0.66
1.25
1.4
1.3
0.95
0.82
nmol/l
0.41
17
302
19
115
1.66
1.25
2.3
4.4
78.68
161.44
nmol/l
1.28
19
115
22
337
0.65
1.22
1.2
1.3
—
—
—
0
0
24
156
1.55
1.20
1.5
1.5
—
—
—
0
0
6
26
2.31
1.18
1.2
1.2
—
—
—
0
0
47
623
0.75
1.17
1.6
2.2
53.25
114.37
ug/min
2.15
26
373
122
1440
0.84
1.13
6.8
9.3
93.60
93.85
%
0.15
122
1432
7
30
2.34
1.12
1.9
2.3
—
—
—
0
0
8
40
2.00
1.12
1.1
1.2
—
—
—
0
0
11
195
0.56
1.11
1.2
1.1
—
33.85
—
0
12
13
74
1.76
1.06
2.2
2.3
—
—
—
0
0
13
74
1.76
1.06
2.2
2.3
—
—
—
0
0
128
1091
1.19
1.06
1.1
1.2
—
—
—
0
0
15
90
1.67
1.04
1.3
1.4
2.29
2.74
u/field
—
7
61
19
122
1.56
1.02
1.5
1.5
—
—
—
0
0
19
122
1.56
1.02
1.5
1.5
—
—
—
0
0
71
874
0.81
1.02
2.7
2.6
—
—
—
0
0
26
369
0.70
1.02
1.3
1.3
—
—
—
0
0
152
1320
1.16
1.02
2.5
2.4
373.21
373.65
nmol/l
0.01
146
1202
215
1918
1.14
0.99
3.4
2.6
64.89
65.87
g/l
1.14
186
1753
1546
15150
1.10
0.98
4.8
5.4
6.27
6.23
mmol/l
0.70
1355
13514
9
51
1.77
0.94
6.8
5.9
13.53
13.42
%
—
9
51
6
120
0.50
0.93
1.0
1.2
—
—
—
0
0
22
313
0.70
0.89
1.1
1.1
—
43.18
—
0
10
7
130
0.54
0.87
3.1
2.3
—
—
—
0
0
19
274
0.69
0.84
1.3
1.4
—
—
—
0
0
30
400
0.75
0.84
1.3
1.5
—
—
—
0
0
35
266
1.32
0.83
7.1
8.0
7.50
7.64
mmol/l
0.08
30
224
43
543
0.79
0.81
2.0
1.7
44.40
46.87
nmol/l
0.34
43
507
52
642
0.80
0.81
1.4
1.3
364.81
312.53
u/ml
0.10
47
580
20
281
0.71
0.78
1.1
1.1
—
—
—
0
0
0
28
0.00
0.76
0.0
1.1
—
—
—
0
0
54
653
0.82
0.71
1.6
1.6
37.73
36.52
u/l
0.17
44
543
225
2451
0.91
0.70
5.7
7.5
94.79
95.26
%
0.40
213
2355
5
91
0.55
0.67
2.2
5.8
57.20
73.80
%
—
5
75
88
763
1.16
0.66
3.0
3.6
212.89
6585.06
u/ml
1.04
75
647
8
129
0.62
0.64
1.5
1.2
90.37
91.36
%
—
8
118
69
804
0.85
0.63
1.6
3.5
112.16
68.64
mg/l
0.27
58
646
6
102
0.59
0.62
1.0
1.1
—
—
—
0
0
68
790
0.86
0.60
1.6
3.5
1.97
3.84
ratio
—
7
59
42
509
0.82
0.59
3.0
2.8
1.90
1.82
mg/l
0.20
37
446
1516
15376
0.93
0.59
4.8
5.7
2.53
2.41
mmol/l
5.00
1318
13868
0
22
0.00
0.59
0.0
6.5
—
—
—
0
0
0
22
0.00
0.59
0.0
1.0
—
—
—
0
0
0
22
0.00
0.59
0.0
4.9
—
—
—
0
0
6
35
1.72
0.57
1.2
1.6
5502.17
627.00
nmol/24h
—
6
35
39
474
0.82
0.57
1.4
1.5
13703.54
15259.89
e6/l
0.17
28
336
5
90
0.55
0.55
1.2
1.2
—
—
—
0
0
47
558
0.84
0.55
1.3
1.3
—
—
—
0
0
70
803
0.87
0.54
1.6
3.5
206.36
52.60
mg/l
0.46
60
652
9
60
1.50
0.54
3.7
2.0
—
—
—
0
0
13
182
0.71
0.54
1.6
1.2
4.83
5.94
u/ml
—
6
84
11
158
0.69
0.52
1.1
1.4
—
—
—
0
0
6
99
0.60
0.52
1.2
1.1
—
—
—
0
0
21
161
1.31
0.51
1.4
1.3
—
—
—
0
0
12
168
0.71
0.50
1.3
1.7
23.40
25.82
u/ml
—
5
39
56
482
1.17
0.50
1.9
2.2
91.70
84.22
%
1.81
56
470
16
118
1.36
0.50
1.5
1.6
101.50
99.92
umol/l
0.04
16
118
34
411
0.82
0.49
1.2
1.3
—
234.29
—
0
14
1423
14433
0.95
0.49
4.0
4.5
1.37
1.27
mmol/l
5.43
1224
12879
1464
14827
0.95
0.46
4.4
5.0
1.34
1.30
mmol/l
3.20
1272
13325
134
1459
0.91
0.46
5.3
6.8
23.80
24.31
mmol/l
0.60
128
1387
67
592
1.14
0.44
1.3
2.4
0.00
0.00
g/l
-0.00
56
546
17
131
1.30
0.42
1.3
1.4
42.96
156.06
pmol/l
4.97
17
131
13
96
1.36
0.41
2.0
2.0
—
—
—
0
0
0
15
0.00
0.41
0.0
1.6
—
—
—
0
0
0
15
0.00
0.41
0.0
1.3
—
0.52
—
0
10
0
17
0.00
0.40
0.0
1.1
—
—
—
0
0
41
352
1.17
0.40
1.1
1.2
—
—
—
0
0
0
18
0.00
0.40
0.0
1.0
—
—
—
0
0
53
465
1.14
0.40
2.1
3.5
50.28
661.55
u/ml
1.66
45
432
8
61
1.31
0.39
1.0
1.2
—
—
—
0
0
28
335
0.83
0.39
2.4
1.6
—
—
—
0
0
7
106
0.66
0.39
1.3
1.5
15.77
15.93
umol/l
—
7
97
0
19
0.00
0.39
0.0
1.0
—
1.48
—
0
10
192
1804
1.07
0.39
1.9
2.3
0.19
0.20
g/l
0.34
178
1655
5
36
1.39
0.38
1.6
1.1
—
—
—
0
0
58
515
1.13
0.37
1.4
2.7
30.93
34.97
umol/l
0.62
53
460
15
191
0.78
0.36
1.1
1.1
—
—
—
0
0
76
839
0.90
0.36
1.2
1.3
141.33
76.25
au/ml
—
6
51
67
605
1.11
0.34
1.3
2.4
0.00
0.00
g/l
0.50
56
547
40
349
1.15
0.34
1.2
1.2
—
—
—
0
0
6
46
1.31
0.33
1.0
1.2
—
—
—
0
0
10
132
0.76
0.32
2.8
3.1
—
—
—
0
0
196
2065
0.94
0.32
2.7
2.4
5.09
8.29
ug/l
4.45
173
1823
44
494
0.89
0.30
1.1
1.2
88.12
107.52
iu/ml
0.21
15
149
13
163
0.80
0.29
1.3
1.1
—
—
—
0
0
7
57
1.23
0.29
1.7
2.3
—
—
—
0
0
1484
14967
0.96
0.28
4.3
5.0
4.37
4.16
mmol/l
10.66
1295
13602
71
654
1.09
0.26
1.3
2.4
0.03
0.05
g/l
0.21
60
595
8
67
1.19
0.26
1.0
1.1
—
—
—
0
0
10
127
0.79
0.25
1.1
1.1
—
—
—
0
0
14
114
1.23
0.25
2.1
2.3
—
—
—
0
0
72
667
1.08
0.24
1.3
2.3
35.25
37.21
g/l
2.09
56
583
38
423
0.90
0.24
1.3
1.6
—
—
—
0
0
6
83
0.72
0.24
1.0
1.3
—
56.46
%
—
0
13
257
2663
0.96
0.24
5.4
7.3
11.52
11.79
kpa
0.43
245
2538
257
2662
0.96
0.23
5.4
7.3
4.84
5.06
kpa
3.31
244
2535
23
200
1.15
0.22
1.3
1.5
—
—
—
0
0
35
389
0.90
0.22
2.2
1.8
112.14
202.17
pmol/l
4.14
28
356
80
749
1.07
0.21
1.5
2.6
1.15
1.36
g/l
0.14
62
640
30
336
0.89
0.21
1.2
1.1
—
—
—
0
0
5
42
1.19
0.21
1.0
1.5
293.20
241.97
%
—
5
37
0
11
0.00
0.21
0.0
1.2
—
—
—
0
0
0
11
0.00
0.21
0.0
1.0
—
—
—
0
0
0
11
0.00
0.21
0.0
8.3
—
—
—
0
0
0
11
0.00
0.21
0.0
7.5
—
—
—
0
0
0
10
0.00
0.21
0.0
1.1
—
—
—
0
0
0
12
0.00
0.21
0.0
1.4
—
—
—
0
0
0
12
0.00
0.21
0.0
1.2
—
—
—
0
0
25
220
1.14
0.21
1.7
3.2
—
—
—
0
0
5
43
1.16
0.21
1.0
1.1
—
—
—
0
0
5
43
1.16
0.21
1.0
1.1
—
—
—
0
0
1332
13429
0.97
0.20
3.6
4.0
2.07
2.08
mu/l
0.04
1157
11881
0
14
0.00
0.20
0.0
1.1
—
—
—
0
0
21
239
0.88
0.19
1.0
1.1
1.17
26.49
iu/ml
—
6
49
258
2659
0.97
0.19
5.3
7.3
0.80
0.96
mmol/l
0.25
197
2061
(3016894) Varicella zoster virus DNA [Presence] in Cerebral spinal fluid by NAA with probe detection
10
81
1.24
0.18
1.0
1.1
—
—
—
0
0
26
232
1.12
0.18
1.2
1.5
71.67
66.35
%
0.32
18
140
86
814
1.06
0.18
1.5
2.5
9.63
10.57
g/l
1.30
69
721
7
58
1.21
0.18
1.6
1.2
—
—
—
0
0
35
319
1.10
0.18
2.4
1.3
7.46
7.64
u/l
0.03
19
258
8
73
1.10
0.15
1.1
1.1
—
—
—
0
0
61
575
1.06
0.15
3.4
3.5
4.43
4.30
pmol/l
0.36
55
504
7
86
0.81
0.14
1.4
1.6
11.00
13.45
nmol/l
—
7
77
45
421
1.07
0.14
1.1
1.2
—
—
—
0
0
29
315
0.92
0.13
1.2
1.4
—
19.39
—
0
10
10
117
0.85
0.13
1.0
1.0
—
—
—
0
0
9
108
0.83
0.13
1.0
1.2
9.91
10.53
mmol/l
—
9
103
9
110
0.82
0.13
2.4
1.6
—
—
—
0
0
27
248
1.09
0.12
1.1
1.2
330.46
283.69
u/ml
0.34
13
149
43
457
0.94
0.12
3.0
2.9
0.83
0.84
nmol/l
0.02
27
339
12
105
1.14
0.11
1.0
1.3
—
—
—
0
0
12
105
1.14
0.11
1.0
1.3
—
—
—
0
0
84
810
1.04
0.10
1.5
2.4
3.48
2.92
g/l
3.74
68
726
5
44
1.14
0.10
1.0
1.1
—
—
—
0
0
5
45
1.11
0.09
1.0
1.1
—
—
—
0
0
5
46
1.09
0.09
1.0
1.1
—
—
—
0
0
5
47
1.06
0.09
1.0
1.1
—
—
—
0
0
13
145
0.90
0.09
1.3
1.2
—
—
—
0
0
6
54
1.11
0.09
1.3
2.6
7.42
8.50
mmol/l
—
6
30
6
56
1.07
0.08
1.2
1.6
2.82
10.44
nmol/l
—
6
51
10
113
0.88
0.08
2.6
2.2
0.16
0.24
e9/l
—
10
105
6
72
0.83
0.07
1.0
1.2
86.33
247.46
iu/ml
—
6
72
8
78
1.03
0.07
1.0
1.1
—
—
—
0
0
7
84
0.83
0.07
1.0
1.4
—
—
—
0
0
7
85
0.82
0.07
1.1
1.2
339.00
353.10
u/l
—
7
79
16
173
0.92
0.06
2.3
1.3
0.84
0.65
nmol/l
1.08
16
164
25
264
0.95
0.06
1.2
1.5
107.33
119.55
u/ml
—
6
60
29
276
1.05
0.06
1.1
1.2
—
—
—
0
0
12
131
0.92
0.05
1.3
1.3
—
47.00
—
0
10
353
3499
1.01
0.05
4.6
4.0
1.02
1.02
kg/l
0.61
69
548
43
415
1.04
0.05
3.9
3.6
34.61
33.95
mg/l
0.04
31
270
32
334
0.96
0.05
1.2
1.1
—
—
—
0
0
10
110
0.91
0.05
2.8
2.9
27.64
34.28
%
—
5
70
22
232
0.95
0.05
4.1
3.4
—
—
—
0
0
12
130
0.92
0.04
1.1
1.2
—
—
—
0
0
46
472
0.97
0.03
1.4
1.5
270.47
251.77
ug/g
0.26
32
304
127
1255
1.01
0.03
6.5
9.4
23.80
24.14
mmol/l
0.58
122
1220
13
122
1.07
0.02
3.4
2.1
368.31
625.60
e6/l
2.21
13
115
11
117
0.94
0.01
1.6
2.4
—
—
—
0
0
22
213
1.03
0.01
1.4
1.7
4.68
4.44
iu/l
—
8
64
34
333
1.02
0.01
1.6
1.5
55343.83
69198.80
e6/l
0.14
18
204
11
115
0.96
0.00
1.0
1.1
—
31.60
—
0
5
13
129
1.01
0.00
1.0
1.0
—
—
—
0
0
37
365
1.01
0.00
1.6
1.5
1443.93
1798.53
e6/l
0.43
28
264
88
879
1.00
0.00
1.5
2.4
8.30
7.30
g/l
3.06
71
794
88
878
1.00
0.00
1.5
2.4
—
—
—
0
0
12
118
1.02
0.00
3.0
2.2
377.83
527.83
e6/l
0.60
12
105
62
617
1.01
0.00
1.5
1.8
—
—
—
0
0
55
547
1.01
0.00
1.4
1.6
—
—
—
0
0
88
877
1.00
0.00
1.5
2.4
4.09
3.72
g/l
0.55
71
793
0
6
0.00
0.00
0.0
1.0
—
—
—
0
0
0
6
0.00
0.00
0.0
1.0
—
—
—
0
0
0
6
0.00
0.00
0.0
1.2
—
—
—
0
0
0
6
0.00
0.00
0.0
1.0
—
—
—
0
0
0
6
0.00
0.00
0.0
1.0
—
—
—
0
0
0
8
0.00
-0.00
0.0
1.0
—
—
—
0
0
6
65
0.92
-0.00
1.0
2.3
165.23
22.18
u/l
—
6
59
0
5
0.00
-0.00
0.0
1.0
—
842.00
—
0
5
9
94
0.96
-0.00
1.0
1.0
—
—
—
0
0
0
7
0.00
-0.00
0.0
4.9
—
343.86
—
0
7
0
5
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.2
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.3
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.6
—
2.02
—
0
5
0
7
0.00
-0.00
0.0
6.4
—
49.00
—
0
7
0
7
0.00
-0.00
0.0
1.1
—
59.04
—
0
7
0
9
0.00
-0.00
0.0
1.1
—
—
—
0
0
0
9
0.00
-0.00
0.0
1.1
—
—
—
0
0
5
58
0.86
-0.00
1.0
1.5
—
—
—
0
0
0
8
0.00
-0.00
0.0
3.6
—
—
—
0
0
0
8
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
8
0.00
-0.00
0.0
1.0
—
—
—
0
0
Mortality – FinRegistry
↥This endpoint is excluded from FinRegistry analyses (omitted endpoint).
Relationships between endpoints
↥Index endpoint: RX_L02BX – L02BX Other hormone antagonists and related agents
GWS hits: -
This endpoint is excluded from FinRegistry analyses (omitted endpoint).